Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma
RATIONALE: Analyzing tissue and blood samples from healthy volunteers or patients with Fanconi anemia, myelodysplasia, myeloproliferative disorders, or myeloma in the laboratory may help doctors learn more about the causes of blood cancers.
PURPOSE: The purpose of this study is to analyze in the laboratory blood and bone marrow cells from healthy volunteers or patients with Fanconi anemia, myeloproliferative disorders, or myeloma.
Chronic Myeloproliferative Disorders
Multiple Myeloma and Plasma Cell Neoplasm
Genetic: microarray analysis
Genetic: polyacrylamide gel electrophoresis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Genetic: reverse transcriptase-polymerase chain reaction
Genetic: western blotting
Other: high performance liquid chromatography
Other: immunoenzyme technique
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Dysregulation of Hematopoiesis in Fanconi Anemia|
- Loss of function analyses [ Time Frame: Duration of the study ]
- Proteins binding to Fanconi anemia, complementation group C (FACC) gene-product by affinity chromatography of nuclear and whole cell lysates of normal cells [ Time Frame: Duration of the study ]
- Screening of proteins binding to FACC gene-product using monoclonal antibodies specific to signal transduction and cell cycle proteins [ Time Frame: Duration of the study ]
- Microsequencing of unique proteins [ Time Frame: Duration of the study ]
- Location of specific downstream block point imposed by antisense molecules using antibodies specific to signal transduction, cell cycle, or repair proteins for the FACC protein [ Time Frame: Duration of the study ]
- Affirmation that the block points identified are recapitulated in progenitor cells from peripheral blood [ Time Frame: Duration of the study ]
- Identification of functional defects in Fanconi anemia hematopoietic stromal cells [ Time Frame: Duration of the study ]
|Study Start Date:||June 1975|
|Estimated Study Completion Date:||January 2020|
|Estimated Primary Completion Date:||January 2020 (Final data collection date for primary outcome measure)|
- Identify the specific molecular function of the Fanconi anemia (FA) complementing gene products in hematopoietic progenitor cells from patients and normal volunteers.
- Identify functional defects in hematopoietic stromal cells, including macrophages, from patients with FA, and selected blood cancers as well as normal volunteers.
OUTLINE: Peripheral blood mononuclear leukocytes, skin fibroblasts, and marrow fibroblasts are collected for loss-of-function and gain-of-function analysis related to the Fanconi anemia complementing gene.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00900055
|United States, Oregon|
|Knight Cancer Institute at Oregon Health and Science University|
|Portland, Oregon, United States, 97239-3098|
|Principal Investigator:||Grover C. Bagby, MD||OHSU Knight Cancer Institute|